CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 29 enrolled
Drug / intervention
Lonafarnibdrug
Likely dose
Lonafarnib 115mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00425607
NCT00425607Phase 2Completed
CompareCT.gov

An Open Label Dose Adjusted Phase II Trial of the Oral Farnesyltransferase Inhibitor (FTI) Lonafarnib (SCH66336) for Patients With Hutchinson-Gilford Progeria Syndrome (HGPS) and Progeroid Laminopathies

Monica E. Kleinman·interventional·Posted Jan 23, 2007·Updated Jun 25, 2019

In Brief

A Phase 2 clinical trial evaluating Lonafarnib for Progeria and Hutchinson-Gilford Syndrome. Completed, enrolled 29 participants across 1 site.

Detailed Summary

This is an open label dose adjusted phase II trial of the oral farnesyltransferase inhibitor (FTI) lonafarnib (SCH66336) for patients with HGPS and progeroid laminopathies.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProgeria, Hutchinson-Gilford Syndrome
CountriesUnited States
CollaboratorsSchering-Plough

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJan 23, 2007
Enrollment StartMay 1, 2007
Primary CompletionOct 1, 2009
TodayJul 2, 2026
Enrollment to primary: 2.4 yearsPosted 19.4 years ago

Interventions

Lonafarnibdrug

Lonafarnib will be taken orally, twice per day, by all patients enrolled on this study. The drug is supplied to patients in capsule form, and for patients who are unable to swallow pills, the drug may be dissolved into solution. Every patient will start lonafarnib therapy at a dose of 115mg/kg. The study allows for patients to receive a dose escalation (up to 150mg/kg) if the drug is being well-tolerated. Every patient enrolled on this study will undergo two years of lonafarnib therapy.